Integrin-linked kinase mediates force transduction in cardiomyocytes by modulating SERCA2a/PLN function

Nature Communications

Volumn 5, Issue , 2014, Pages

  Traister, Alexandra ^a   Li, Mark ^a   Aafaqi, Shabana ^a   Lu, Mingliang ^a   Arab, Sara ^b   Radisic, Milica ^c   Gross, Gil ^a   Guido, Fiorella ^a   Sherret, John ^a   Verma, Subodh ^d   Slorach, Cameron ^a   Mertens, Luc ^a   Hui, Wei ^a   Roy, Anna ^a,e   Delgado Olguín, Paul ^a,e,f   Hannigan, Gregory ^g   Maynes, Jason T ^a,h   Coles, John G ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); INTEGRIN LINKED KINASE; PHOSPHOLAMBAN; PLECKSTRIN; REGULATOR PROTEIN; SARCOPLASMIC ENDOPLASMIC RETICULUM CALCIUM ATPASE ISOFORM 2A; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; INTEGRIN-LINKED KINASE; PROTEIN SERINE THREONINE KINASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

CARDIOLOGY; ENZYME ACTIVITY; HOMOLOGY; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; MECHANORECEPTOR; MECHANOTRANSDUCTION; MOUSE; NONHUMAN; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; ANIMAL; GENETICS; HEART CONTRACTION; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PLURIPOTENT STEM CELL; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM-BINDING PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MECHANOTRANSDUCTION, CELLULAR; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84923374863     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5533     Document Type: Article

References (69)

1. Serio, A., Narula, N., Kodama, T., Favalli, V. & Arbustini, E. Familial dilated cardiomyopathy. Clinical and genetic characteristics. Herz 37, 822-829 (2012).
2. McNally, E. M., Golbus, J. R. & Puckelwartz, M. J. Genetic mutations and mechanisms in dilated cardiomyopathy. J. Clin. Invest. 123, 19-26 (2013).
3. Marks, A. R. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J. Clin. Invest. 123, 46-52 (2013).
4. Glaves, J. P., Trieber, C. A., Ceholski, D. K., Stokes, D. L. & Young, H. S. Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump. J. Mol. Biol. 405, 707-723 (2010).
5. Kranias, E. G. & Hajjar, R. J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ. Res. 110, 1646-1660 (2012).
6. Neumann, J. et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell Cardiol. 29, 265-272 (1997).
7. Jessup, M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304-313 (2011).
8. Hulot, J. S., Senyei, G. & Hajjar, R. J. Sarcoplasmic reticulum and calcium cycling targeting by gene therapy. Gene Ther. 19, 596-599 (2012).
9. Frank, D. & Frey, N. Cardiac Z-disc signaling network. J. Biol. Chem. 286, 9897-9904 (2011).
10. Meder, B. et al. PINCH proteins regulate cardiac contractility by modulating integrin-linked kinase-protein kinase B signaling. Mol. Cell Biol. 31, 3424-3435 (2011).
11. Bendig, G. et al. Integrin-linked kinase, a novel component of the cardiac mechanical stretch sensor, controls contractility in the zebrafish heart. Genes Dev. 20, 2361-2372 (2006).
12. Hannigan, G. E., Coles, J. G. & Dedhar, S. Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. Circ. Res. 100, 1408-1414 (2007).
13. Knoll, R. et al. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 116, 515-525 (2007).
14. White, D. E. et al. Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev. 20, 2355-2360 (2006).
15. Lu, H. et al. Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation 114, 2271-2279 (2006).
16. Ibrahim, M., Gorelik, J., Yacoub, M. H. & Terracciano, C. M. The structure and function of cardiac t-tubules in health and disease. Proc. Biol. Sci. 278, 2714-2723 (2011).
17. Sun, N. et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra147 (2012).
18. Maillet, M., van Berlo, J. H. & Molkentin, J. D. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Mol. Cell Biol. 14, 38-48 (2012).
19. Lossner, D. et al. Integrin alphavbeta3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription. J. Cell Physiol. 220, 367-375 (2009).
20. Mattiazzi, A. & Kranias, E. G. The role of CaMKII regulation of phospholamban activity in heart disease. Front. Pharmacol. 5, 5 (2014).
21. Schwinger, R. H. et al. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2 + uptake and Ca(2+ )-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92, 3220-3228 (1995).
22. Movsesian, M. A., Karimi, M., Green, K. & Jones, L. R. Ca(2+ )-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 90, 653-657 (1994).
23. Kattman, S. J., Koonce, C. H., Swanson, B. J. & Anson, B. D. Stem cells and their derivatives: a renaissance in cardiovascular translational research. J. Cardiovasc. Transl. Res. 4, 66-72 (2011).
24. Ma, J. et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017 (2011).
25. Miura, T. & Miki, T. GSK-3beta, a therapeutic target for cardiomyocyte protection. Circ. J. 73, 1184-1192 (2009).
26. Li, J. et al. Remote preconditioning provides potent cardioprotection via PI3K/Akt activation and is associated with nuclear accumulation of beta-catenin. Clin. Sci. (Lond) 120, 451-462 (2011).
27. Hannigan, G. E., McDonald, P. C., Walsh, M. P. & Dedhar, S. Integrin-linked kinase: not so 'pseudo' after all. Oncogene 30, 4375-4385 (2011).
28. Maydan, M. et al. Integrin-linked kinase is a functional Mn2 +-dependent protein kinase that regulates glycogen synthase kinase-3beta (GSK-3beta) phosphorylation. PLoS ONE 5, e12356 (2010).
29. Durbin, A. D., Pasic, I., Wong, D. K., Hannigan, G. E. & Malkin, D. The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. Cell Cycle 9, 1951-1959 (2010).
30. Witcher, D. R., Strifler, B. A. & Jones, L. R. Cardiac-specific phosphorylation site for multifunctional Ca2 +/calmodulin-dependent protein kinase is conserved in the brain ryanodine receptor. J. Biol. Chem. 267, 4963-4967 (1992).
31. Maier, L. S. Ca(2 +)/calmodulin-dependent protein kinase II (CaMKII) in the heart. Adv. Exp. Med. Biol. 740, 685-702 (2012).
32. Fukuda, K., Knight, J. D., Piszczek, G., Kothary, R. & Qin, J. Biochemical, proteomic, structural, and thermodynamic characterizations of integrin-linked kinase (ILK): cross-validation of the pseudokinase. J. Biol. Chem. 286, 21886-21895 (2011).
33. Persad, S. et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 276, 27462-27469 (2001).
34. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562 (2009).
35. Lange, A. et al. Integrin-linked kinase is an adaptor with essential functions during mouse development. Nature 461, 1002-1006 (2009).
36. Marechal, X. et al. Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Clin. Sci. (Lond) 121, 405-413 (2011).
37. Chatterjee, K., Zhang, J., Honbo, N. & Karliner, J. S. Doxorubicin cardiomyopathy. Cardiology 115, 155-162 (2009).
38. Khouri, M. G. et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 126, 2749-2763 (2012).
39. Arola, O. J. et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 60, 1789-1792 (2000).
40. von Harsdorf, R., Li, P. F. & Dietz, R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 99, 2934-2941 (1999).
41. Vinogradova, T. M. et al. Sarcoplasmic reticulum Ca2 + pumping kinetics regulates timing of local Ca2 + releases and spontaneous beating rate of rabbit sinoatrial node pacemaker cells. Circ. Res. 107, 767-775 (2010).
42. Prasad, A. M. et al. Differential control of calcium homeostasis and vascular reactivity by Ca2 +/calmodulin-dependent kinase II. Hypertension 62, 434-441 (2013).
43. Nunes, S. S. et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 10, 781-787 (2013).
44. Eisner, D., Bode, E., Venetucci, L. & Trafford, A. Calcium flux balance in the heart. J. Mol. Cell Cardiol. 58, 110-117 (2013).
45. Olson, R. D. et al. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc. Toxicol. 5, 269-283 (2005).
46. Jonsson, M. K., Wang, Q. D. & Becker, B. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay Drug. Dev. Technol. 9, 589-599 (2011).
47. Xi, B. et al. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J. Lab. Autom. 16, 415-421 (2011).
48. Durbin, A. D. et al. JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J. Clin. Invest. 119, 1558-1570 (2009).
49. Neilan, T. G. et al. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur. Heart J. 27, 1868-1875 (2006).
50. Sawaya, H. et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am. J. Cardiol. 107, 1375-1380 (2011).
51. Sawaya, H. et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ. Cardiovasc. Imaging 5, 596-603 (2012).
52. Nguemo, F. et al. In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell Physiol. Biochem. 29, 819-832 (2012).
53. Lyon, A. R. et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ. Arrhythm. Electrophysiol. 4, 362-372 (2011).
54. Lipskaia, L., Chemaly, E. R., Hadri, L., Lompre, A. M. & Hajjar, R. J. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin. Biol. Ther. 10, 29-41 (2010).
55. Lokuta, A. J. et al. Increased nitration of sarcoplasmic reticulum Ca2 +-ATPase in human heart failure. Circulation 111, 988-995 (2005).
56. Swaminathan, P. D., Purohit, A., Hund, T. J. & Anderson, M. E. Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ. Res. 110, 1661-1677 (2012).
57. Cheng, J. et al. CaMKII inhibition in heart failure, beneficial, harmful, or both. Am. J. Physiol. Heart Circ. Physiol. 302, H1454-H1465 (2012).
58. Previlon, M., Pezet, M., Dachez, C., Mercadier, J. J. & Rouet-Benzineb, P. Sequential alterations in Akt, GSK3beta, and calcineurin signalling in the mouse left ventricle after thoracic aortic constriction. Can. J. Physiol. Pharmacol. 88, 1093-1101 (2010).
59. Cortes, R. et al. Differences in MEF2 and NFAT transcriptional pathways according to human heart failure aetiology. PLoS ONE 7, e30915 (2012).
60. Devalliere, J. et al. LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets alpha-parvin to control cell adhesion and migration. FASEB J. 26, 2592-2606 (2013).
61. Moik, D. et al. Mutations in the paxillin-binding site of integrin-linked kinase (ILK) destabilize the pseudokinase domain and cause embryonic lethality in mice. J. Biol. Chem. 288, 18863-18871 (2013).
62. Herranz, B. et al. Integrin-linked kinase regulates vasomotor function by preventing endothelial nitric oxide synthase uncoupling: role in atherosclerosis. Circ. Res. 110, 439-449 (2012).
63. Xie, J. et al. The impairment of ILK related angiogenesis involved in cardiac maladaptation after infarction. PLoS ONE 6, e24115 (2011).
64. Traister, A. et al. Mutation in integrin-linked kinase (ILKR211A) and heat-shock protein 70 comprise a broadly cardioprotective complex. PLoS ONE 8, e77331 (2013).
65. Aoyagi, Y., Fujita, N. & Tsuruo, T. Stabilization of integrin-linked kinase by binding to Hsp90. Biochem. Biophys. Res. Commun. 331, 1061-1068 (2005).
66. Tilemann, L., Ishikawa, K., Weber, T. & Hajjar, R. J. Gene therapy for heart failure. Circ. Res. 110, 777-793 (2012).
67. Bolsover, S., Ibrahim, O., O'Luanaigh, N., Williams, H. & Cockcroft, S. Use of fluorescent Ca2+ dyes with green fluorescent protein and its variants: problems and solutions. Biochem. J. 356, 345-352 (2001).
68. Barrett, K. T. et al. Subtle alterations in breathing and heart rate control in the 5-HT1A receptor knockout mouse in early postnatal development. J. Appl. Physiol. 113, 1585-1593 (2012).
69. Pongprot, Y., Sittiwangkul, R., Charoenkwan, P. & Silvilairat, S. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer. J. Pediatr. Hematol. Oncol. 34, 589-595 (2012).